AATS: Single Dose of EPO Pre-Cardiac Op Cuts Need for Blood
High dose of human recombinant erythropoietin two days pre-op benefits cardiac surgery patients
WEDNESDAY, May 8 (HealthDay News) -- A single high dose of human recombinant erythropoietin (HRE) administered two days before cardiac surgery is associated with reduced need for transfused blood, according to a study presented at the annual meeting of the American Association for Thoracic Surgery, held from May 4 to 8 in Minneapolis.